5 Dec, 2017

SpagoNanomedical select ChemConnection for SpagoPix production to supply clinicaltrials

Spago Nanomedical AB has signed an agreement with ChemConnection BV, a well-established contract manufacturer with extensive experience in the GMP-production of nanomedical products, for the manufacture of the SpagoPix product candidate SN132D for clinical trials.

The SpagoPix project is advancing towards clinical trials and the product candidate SN132D is currently undergoing regulatory preclinical tests to generate the toxicity and safety data required to initiate human studies.

The production of material will commence in the first half of 2018. Tech transfer in which Spago Nanomedical transfers the production process developed by the company during the past year, starts immediately.

"We look forward to starting the GMP production of SN132D and continue preparations for clinical trials," says Oskar Axelsson, CSO of Spago Nanomedical.
"We are proud that we can contribute to the development of this exciting new product with the manufacture of clinical batches" says Gerjan Kemperman, CEO of ChemConnection.